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Abstract
The aminoglycoside antibiotic gentamicin elicits proximal tubular toxicity and cell death. In calcium-sensing receptor (CaR)-transfected HEK-
293 (CaR-HEK) cells and CaR-expressing proximal tubule-derived opossum kidney (OK) cells, chronic gentamicin treatment elicits dose-
dependent, caspase-mediated apoptotic cell death. Here we investigated whether the renal cell toxicity of the CaR agonist gentamicin could be
prevented by CaR antagonism or by lithium cotreatment which may interfere with receptor-mediated signalling. Chronic treatment of OK and
CaR-HEK cells with low concentrations of gentamicin elicited cell death, an effect that was ameliorated by cotreatment with the CaR negative
allosteric modulator (calcilytic) NPS-89636. This calcilytic also attenuated CaR agonist-induced ERK activation in these cells. In addition, 1 mM
LiCl, equivalent to its therapeutic plasma concentration, also inhibited gentamicin-induced toxicity in both cell types. This protective effect of
lithium was not due to the disruption of phosphatidylinositol-mediated gentamicin uptake as the cellular entry of Texas red-conjugated gentamicin
into OK and CaR-HEK cells was unchanged by lithium treatment. However, the protective effect of lithium was mimicked by glycogen synthase
3β inhibition. Together, these data implicate CaR activation and a lithium-inhibitable signalling pathway in the induction of cell death by
gentamicin in renal epithelial cells in culture.
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The aminoglycoside antibiotics (AGAs) are an effective and
economical treatment for life-threatening, Gram-negative
infections. However, the clinical usefulness of the AGAs is
limited by their toxicity in the renal proximal tubule as well as
their ototoxicity [1]. We have shown previously that proximal
tubule-derived opossum kidney (OK) cells express a calcium-
sensing receptor (CaR)-like protein and elicit typical responses
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doi:10.1016/j.bbadis.2008.01.003nic exposure of OK cells to gentamicin, or indeed other CaR
agonists such as spermine or poly-arginine, promotes cell death
[3]. In addition, the effect of gentamicin on cell-fate was also
investigated using HEK-293 cells and it was found that cells
transfected with the CaR were considerably more susceptible to
AGA toxicity than non-transfected or empty vector-transfected
controls. Thus, given that CaR is expressed at the apical surface
of the proximal tubule [4,5], where gentamicin-induced ne-
phrotoxicity occurs, and where the acidic conditions enhance
the potency of gentamicin as a CaR agonist [6], these cell cul-
ture data suggest that the CaR could contribute to AGA nephro-
toxicity. However, in the absence of pharmacological inhibitors
of the receptor it has not been previously possible to confirm an
involvement of CaR in AGA-mediated cellular toxicity. Fur-
thermore, the concentrations of gentamicin employed in the
previous cell culture studies were at least an order of magnitude
Fig. 1. Gentamicin induces cell death in CaR-HEK and OK cells at low con-
centrations. CaR-HEK cells were treated for 6 days with 20, 50 or 100 μM
gentamicin, with addition of fresh serum (1%) to each dish at Day 3. Cell death
was then determined by trypan blue exclusion (panel A, N=7–8) including
both floating and adherent cells. Alternatively, OK cells were treated for 7 days
with 50 μMgentamicin, with addition of fresh serum (1%) to each dish at Day 3
and then cell death quantified as before (panel B, N=12). ⁎⁎⁎Pb0.001 vs
control; +++Pb0.001 vs all others by ANOVA.
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tribution of CaR to AGA toxicity in renal cell culture could not
be demonstrated directly. Therefore, here we began by assessing
the contribution of the CaR to AGA renal cell toxicity by testing
whether a negative allosteric modulator of CaR, the calcilytic
NPS-89636, exerted a protective effect in renal-derived cells
treated chronically with therapeutically relevant concentrations
of gentamicin.Fig. 2. Cotreatment with the calcilytic NPS-89636 attenuates gentamicin-induced cel
cells were treated for 4 days with 200 (panel Ai, N=10) or 500 μM gentamicin (pa
vehicle added to controls) and cell death determined by trypan blue exclusion. Alterna
presence or absence of 500 nMNPS-89636, with addition of fresh serum (1%) to each
⁎⁎Pb0.0.1, ⁎⁎⁎Pb0.001 vs control; +Pb0.05, ++Pb0.01 vs gentamicin by ANOVA.
or 100 μM gentamicin in the presence or absence of NPS-89636 (500 nM) for 5 min
ERK content was then determined by immunoblotting using a phospho-specific anti-E
ERK2 polyclonal antibody.Despite being first described as a mood stabilizer in 1949 [7],
lithium currently remains an effective and inexpensive treatment
for bipolar disorder [8]. Its therapeutic mechanism of action may
result from its interference in phosphatidylinositol turnover [9]
given the inhibitory effect of lithium on inositol monopho-
sphatase [10,11]. However, more recently the ability of lithium
to inhibit glycogen synthase kinase (GSK)-3β [12] has been one
of a number of mechanisms postulated to explain its therapeutic
effect [13]. In the context of AGA nephrotoxicity, it has been
reported that in rats injected with gentamicin for 5 days, con-
current therapy with lithium decreased the gentamicin-induced
formation of renal lysosomal myeloid bodies [14], possibly via
interference of lithium with phosphoinositide turnover. As a
hydrophilic, polycationic drug, gentamicin binds negatively-
charged phospholipid bilayers and as such this binding could
contribute to the cellular uptake of gentamicin, at least in as-
sociation with the binding of the drug to the megalin / cubilin
complex [15,16]. Therefore, we then tested whether lithium
could ameliorate gentamicin-induced toxicity in OK and CaR-
HEK cells, and whether it did so by affecting drug uptake or
not.
2. Materials and methods
2.1. Materials
Unless otherwise stated, items were obtained from Sigma-Aldrich (Poole,
Dorset, UK) or from sources described previously [3]. GSK-3β inhibitor XI
(3-(1-(3-Hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazin-2-yl-l death and CaR-induced ERK activation in CaR-HEK and OK cells. CaR-HEK
nel Aii, N=5) in the presence or absence of 1 μM NPS-89636 (0.01% DMSO
tively, OK cells were treated for 7 days with or without 100 μMgentamicin in the
dish at Day 3 and then cell death quantified as before ( panel B, N=7). ⁎Pb0.05,
Panel C, CaR-HEK (i) or OK cells (ii) were stimulated with either 5 mM Ca2+o,
at 37 °C and then lysed in RIPA buffer as described in Methods. The phospho-
RK antiserum and the total levels of ERK shown to be unchanged using an anti-
Fig. 3. Cotreatment with lithium ameliorates gentamicin-induced cell death in
CaR-HEK and OK cells. CaR-HEK cells were treated for 4 days with 500 μM
gentamicin ( panel A, N=4–5) in the presence or absence of 1 mM LiCl. Cell
death was then determined by trypan blue exclusion. Alternatively OK cells
received the same 4 day treatments ( panel B, N=8–10). ⁎⁎Pb0.01 vs all others,
by ANOVA.
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oxime) were purchased from Calbiochem.
2.2. Cell Culture
Opossum kidney (OK) cells (used within 12–23 passages of purchase from
the American Type Culture Collection, Rockville, MD) and HEK-293 cells,
stably transfected with human parathyroid CaR (CaR-HEK) [17], were a giftFig. 4. Flow cytometric analysis of lithium cotreatment on gentamicin-induced CaR-
flasks with 500 μM gentamicin in the presence or absence of 1 mM LiCl with sub
cytometry (FACS Vantage). Panel B, Histogram showing the pooled cell death data (
gentamicin vs lithium and gentamicin by t-test. Panel C, 2-Dimensional plot showing
and C, the data shown represent the median responses. Gentamicin increased the propo
exclusively of PI-positive cells) and this effect was ameliorated by LiCl cotreatmenfrom Dr. E.F. Nemeth (NPS Pharmaceuticals, Inc., Salt Lake City, Utah, USA)
and were cultured as described previously [2,3].
2.3. Cell death counting
Cells (60–70% confluency, 35 mm dishes) were incubated in medium
containing 1% serum supplemented with various treatments for up to 4 days, or
for up to 7 days with an addition of 1% serum after 3 days to maintain viability.
Adherent cells were mixed 1:1 (v/v) with 0.4% Trypan Blue solution. Viable
cells (Trypan Blue-excluded) and non-viable cells (Trypan-Blue stained, in-
cluding cells floating in the medium) were counted on a light microscope using a
Neauber's counting slide.
2.4. ERK activation assay
Cells were grown to 80–90% confluence in 35 mm culture dishes and ERK
phosphorylation assayed as described previously [2,3]. Briefly, cells were incu-
bated at 37 °C prior to lysis on ice in RIPA buffer supplemented with protease
and phosphatase inhibitors and proteins resolved by SDS-PAGE prior to
immunoblotting using total ERK and phospho-specific ERK antibodies.
2.5. Flow cytometric DNA analysis
Cells grown in culture flasks were treated as above and then resuspended in
serum-free medium containing propidium iodide (10 μg/ml). Flow cytometric
analysis was performed using a FACS Vantage flow cytometer equipped with an
Enterprise laser (Innova Technology; laser excitation at 488 nm, 250 mV). Red
fluorescence (DNA-bound propidium) was detected at 630±22 nm and acquiredHEK cell death. Panel A, CaR-HEK cells were treated for 4 days in T75 culture
sequent cell death assessed by propidium iodide uptake as quantified by flow
±s.e.m.) from three independent experiments (including 11 replicates). ⁎Pb0.05
the cell size and granularity profiles of the cells shown in panel A. In panels A
rtion of smaller, more granular cells (marked by a polygon and consisting almost
t.
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also recorded to indicate cell size and granularity, respectively. A total of 10,000
cells were analyzed per sample and Cell-Fit software (Becton Dickinson) was
used to evaluate the data.
2.6. Texas red gentamicin internalisation
HEK-293 cells, transfected with either pcDNA3.1 or EGFP tagged CaR
(CaR-EGFP) [6] vectors were incubated at 37 °C in prewarmed HEPES-buffered
physiological saline containing Texas red-conjugated gentamicin (TRG, 1 mg/
ml; Molecular Probes, Eugene, OR) for 30 min as described previously [3]. After
fixation, the relative levels of TRG uptake were studied by confocal microscopy
using anUltraview confocal optical scanner with aKr/Ar laser (Perkin Elmer Life
Sciences, Cambridge, UK) mounted on an Olympus IX70 inverted microscope.
Images were acquired with an Ultrapix CCD digital camera and processed using
Perkin Elmer UltraView software package. Laser intensity, shutter speed and
image capture speed were constant throughout the acquisition process of each
experiment. Quantification of TRG internalisation was performed using a
FLUOstar microplate basedmulti-detection reader (BMGLabtech, Durham, NC,
USA).
2.7. Statistical analysis
Unless otherwise stated, data are presented as means±S.E. and statistical
significance determined by one-way ANOVA (Tukey Post-Hoc test; Pb0.05).3. Results
We have shown previously that 4 day exposure of proximal
tubule-derived OK cells to 500 μM gentamicin elicits cell deathFig. 5. Flow cytometric analysis of lithium cotreatment on gentamicin-induced OK cel
in the presence or absence of 1 mM LiCl were processed for cell death analysis by
increase in the proportion of PI-positive cells (panels A and B) and the proportion
⁎⁎Pb0.01 gentamicin vs lithium & gentamicin by t-test (N=5).and that increased cell death was observed in CaR-HEK cells
following chronic exposure to 200 μM gentamicin [3]. How-
ever, the slow evolution of acute renal failure (depression of
the GFR) does not normally manifest itself clinically before
5–7 days of treatment, underlying complications notwith-
standing [1,18,19]. In addition, the gentamicin concentrations
used previously in our cell culture study were an order of
magnitude greater than the target plasma concentration aimed for
in antibiotic therapy [1]. We therefore examined whether
reproducing conditions resembling more closely those achieved
therapeutically (i.e., more prolonged exposures and use of lower
concentrations of the drug) we could still observe cytotoxicity.
Our results show that, indeed, chronic treatment for 6–7 dayswith
20–100 μM gentamicin elicited significant cell death in CaR-
HEK cells (Fig. 1A). Similarly, OK cells exhibited significant cell
death when treated with 50 μMgentamicin (Fig. 1B). These dead
cells included both floating cells and trypan blue-stained adherent
cells.
To demonstrate more conclusively a role for CaR in the
development of AGA-induced cellular injury, we used a CaR
negative allosteric modulator. Cotreatment with the calcilytic
NPS-89636 resulted in a significant reduction in CaR-HEK cell
death in response to high concentrations of gentamicin (i.e.,
500 μM) and completely ablated the toxic effect of 200 μM
when the drugs were administered for 4 days only (Fig. 2A).
When OK cells were cotreated with NPS-89636, a significant
attenuation (−77%, Pb0.05) of gentamicin (100 μM, 7 days)l death. OK cells treated for 4 days in T75 culture flasks with 500 μMgentamicin
flow cytometry as described in the Legend to Fig. 4. The gentamicin-induced
of smaller, more granular cells (panel C) was attenuated by LiCl cotreatment.
Fig. 6. Lithium cotreatment fails to prevent Texas red-Gentamicin uptake into CaR-HEK and OK cells. Panel A, HEK cells, transfected stably with either empty vector
(pcDNA3.1/hygro) or human CaR, were preincubated for 10 mins in the presence or absence of 1 mM LiCl and then incubated for 30 min in Texas red-conjugated
gentamicin (TRG)±LiCl. Following cell washing to remove excess TRG, microfluorescence imaging revealed equivalent gentamicin uptake in both sets of cells.
Panel B, An identical experiment was performed on OK cells. Representative fluorescence images are presented (i) together with a histogram showing relative
fluorescence unit (rfu) levels indicative of TRG uptake (ii). Image exposure times were identical for cell fluorescence within each experiment e.g. TRG±lithium.
Results are from three independent experiments performed at least in duplicate.
Fig. 7. Inhibitors of glycogen synthase kinase-3 attenuate gentamicin-induced
cell death in OK and CaR-HEK cells. Panel A, CaR-HEK cells were treated for
4 days with 500 μM gentamicin in the presence or absence of 1 mM LiCl or
200 nM GSK-3β inhibitor XI and then cell death was then determined by trypan
blue exclusion. Panel B, OK cells were treated as in A, but instead cotreated with
either GSK-3 inhibitor XI or IX (20 nM). ⁎⁎⁎Pb0.001 vs control; +Pb0.05,
++Pb0.01 vs gentamicin, by ANOVA; (N≥7).
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inhibits CaR-mediated responses in these cells, OK and CaR-
HEK cells were stimulated with either 5 mM Ca2+o or 200 μM
gentamicin in the presence or absence of the calcilytic and then
tested for extracellular-regulated kinase (ERK) phosphorylation
/ activation, a well-established functional readout for CaR acti-
vation [2,20]. Whilst both high Ca2+o concentration and gen-
tamicin elicited ERK activation, as demonstrated previously [2],
cotreatment with NPS-89636 blocked these responses in both
cell types (Fig. 2C).
There is evidence that lithium may interfere with gentamicin
nephrotoxicity in rats [14]. To determine whether lithium exerts
its effect directly on renal cells, or via a more systemic effect, we
studied gentamicin-induced cell death in both OK cells and CaR-
HEK cells in the presence or absence of the clinical target
concentration of LiCl (1 mM). Indeed, LiCl cotreatment sig-
nificantly inhibited the cytotoxicity of gentamicin in CaR-HEK
(Fig. 3A) and OK cells (Fig. 3B) as determined by Trypan Blue
exclusion. These data were supported by flow cytometry ex-
periments in which lithium cotreatment ameliorated gentamicin-
induced cell death in both the CaR-HEK cells (Fig. 4) and OK
cells (Fig. 5). In the flow cytometry experiments, the dead
cells were those exhibiting increased propidium iodide uptake
(Panel A), as well as decreased forward scatter (size) and in-creased side scatter (granularity; Panel C) indicative of apoptosis
[3].
Deterioration of proximal tubular function observed as a
consequence of AGA toxicity in patients has been traditionally
ascribed to drug endocytosis and its sequestration into lyso-
somes, with formation of myeloid bodies and phospholipidosis
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lithium occurs by inhibiting gentamicin internalisation, we
employed a texas red-conjugated form of gentamicin (TRG) [3].
Interestingly, lithium did not appear to reduce gentamicin cel-
lular uptake. Confocal images of CaR-EGFP-transfected HEK
cells (Fig. 6A) and OK cells (Fig. 6B) pretreated with LiCl
(1 mM, 30 min) and then incubated in TRG (+1 mM LiCl,
30 min, 37 °C) showed similar levels of TRG uptake compared
to that observed in non-lithium treated cells. These observations
were reproduced using a quantitative fluorometric assay (OK
cells, PN0.05) (Fig. 6Bii).
Finally, lithium is a known inhibitor for glycogen synthase
kinase (GSK)-3β and inhibition of this kinase could contribute
to the apparent cell-protective effect of lithium [23]. Therefore,
we investigated whether GSK-3β inhibition is capable of atten-
uating gentamicin-induced cell death in OK and CaR-HEK cells.
Indeed, the GSK-3β inhibitor XI inhibited (500 μM) gentami-
cin-induced cell death in CaR-HEK (Fig. 7A) and OK (Fig. 7B)
cells, whilst the GSK-3 Inhibitor IX also inhibited gentamicin
toxicity in the OK cells (Fig. 7B).
4. Discussion
Here we provide pharmacological evidence that the CaR is
capable of mediating AGA-induced toxicity in cultured pro-
ximal tubule-derived cells and that such cellular toxicity can be
ameliorated by lithium cotreatment. The CaR negative allosteric
modulator (calcilytic) NPS-89636 has been shown previously to
inhibit high [Ca2+]o-induced mineralisation in fetal rat calvarial
cells [24], and in CaR-HEK cells to inhibit calcimimetic-induced
actin polymerisation [25] and CaRT888 phosphorylation [26].
Other calcilytics have been shown to stimulate PTH secretion in
rats and isolated bovine parathyroid cells [27–29] as well as
inhibiting inositol phosphate metabolism and Ca2+i mobilisation
in CaR-HEK cells [27,29,30]. Here we demonstrate that NPS-
89636 inhibits acute high [Ca2+]o- and gentamicin-induced ERK
activation and chronic gentamicin-induced cell death in OK and
CaR-HEK cells. Initially, 1 μM NPS-89636 was employed
(Fig. 2A) as was used previously [24–26] however in later
experiments (Fig. 2B and C) 500 nM was found to be equally
effective. The simplest explanation for these data is that NPS-
89636 is acting by inhibiting CaR activity, presumably by de-
creasing receptor agonist sensitivity. This observation is sup-
ported by our previous studies in which we have demonstrated
CaR expression and function in OK cells [2] and shown [3] that
OK cell death can also be induced by the CaR agonists spermine
[31] and poly-arginine [32]. Furthermore, we have shown pre-
viously that using similar gentamicin concentrations, the drug
elicits significant apoptotic cell death in CaR-HEK cells but not
in HEK cells stably transfected with the empty vector alone [3].
Thus, it would be interesting to determine whether calcilytic
cotreatment protects gentamicin-injected rats from proximal
tubule injury.
Variations in basal cell death levels between experiments
were observed. The precise amount of basal cell death recorded
in any experiment depends on a variety of factors including the
rate of growth of the cells, the depletion of nutrients, space andgrowth factors, as well as themethod bywhich cells are collected
and cell death quantified. In general however, we found both
here and previously (3) that the relative toxic effect of genta-
micin tended to be quite consistent. With regards the gentamicin
exposure conditions it should be noted that the drug was present
in the media throughout the 4–6 day treatments whereas with
clinical use, daily peaks and troughs in plasma gentamicin
concentration would alter the pharmacodynamics of proximal
tubular exposure to the drug. The possible consequence, if any,
of such a difference is unclear and thus an in vivo study will be
necessary to confirm the significance of the cell study.
We also demonstrated a protective effect of lithium on
gentamicin-induced cell death in the renal-derived cells. The
effect was significant though partial in some experiments
(Figs. 4 and 7), but complete in others (Figs. 3 and 5). Whether
higher concentrations of lithium would have consistently ab-
lated gentamicin-induced apoptosis was not tested. The 1 mM
lithium treatment used here was chosen deliberately to corre-
spond to the target therapeutic plasma concentration employed
in bipolar disorders. Since alternative theories of gentamicin
nephrotoxicity involve AGA endocytosis [18], then one pos-
sible explanation for the apparent protective effect of lithium
would be that it attenuates gentamicin cellular uptake by inter-
fering with the turnover of negatively-charged inositol phos-
pholipids with which gentamicin would bind on the membrane.
However, at the gentamicin concentration tested, lithium failed
to reduce the acute cellular uptake of Texas red-conjugated
gentamicin into the CaR-HEK or OK cells, despite decreasing
the chronic toxicity of the AGA. Therefore, since lithium can
also interfere in the glycogen synthase kinase-mediated path-
way, which is involved in the regulation of cell fate [23], we
tested the effect of GSK-3β inhibitors and found that they also
inhibited gentamicin-induced CaR-HEK and OK cell toxicity.
Our observations implicate GSK-3β signalling in the mediation
of the CaR-mediated gentamicin toxicity seen here, possibly via
the GSK3/Wnt/β-catenin pathway. Whilst this does not prove
that the protective effect of lithium occurs via GSK-3β inhi-
bition, there at least appears to be good correlation between the
protective effects of lithium and of the GSK-3β inhibitor XI. In
the brain, the neuroprotective effect of lithium treatment has
been associated with altered expression of pro-and anti-apo-
ptotic proteins such as BAX and Bcl-2 respectively [33] and this
may play a role here. In any case, we propose that lithium
should now be tested in rats to determine whether it may serve
as an effective ameliorant for AGA-induced nephrotoxicity. In
this regard, lithium has already been shown to reduce the for-
mation of lysosomal myeloid bodies in rat renal cortex fol-
lowing chronic gentamicin treatment [14]. It should be noted
that while we have shown that lithium fails to reduce total TRG
uptake into the cells while attenuating gentamicin toxicity, we
cannot rule out the possibility that lithium may divert the
gentamicin from one intracellular locale to another one in which
the AGA exerts reduced toxicity. In this regard, others have
shown that porcine, proximal tubular-derived LLC-PK1 cells
traffic TRG rapidly to the endoplasmic reticulum and then on to
the cytosol and nucleus [34] and thus lithium could act by
interfering with such a process.
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include the impairment of glucose, protein and ion transport
[18] as well as numerous biochemical abnormalities [18,35].
Since gentamicin elicits OK cell toxicity over a similar 6-day
time course to the appearance of nephrotoxicity in humans and
at concentrations as low as 50 μM, we would propose that
future cellular studies of gentamicin toxicity should use con-
centrations of drug much closer to the target plasma concen-
tration in humans [1]. At high concentrations, the AGAs exhibit
non-cell specific cytotoxicity by interfering with protein trans-
lation and are indeed often employed as selection agents in
mammalian expression systems. Therefore, high gentamicin
concentrations may induce cytotoxicity by means not related to
the clinical nephrotoxic mechanism, especially given that gen-
tamicin is not generally cytotoxic in other organs (except for
its ototoxicity) during clinical therapy. In an elegant series of
experiments, El Mouedden et al. demonstrated that rats re-
ceiving low dose gentamicin treatment, i.e. at low multiples of
the therapeutic dose, exhibit proximal tubule cell apoptosis
whereas higher doses of drug were required to elicit acute tu-
bular necrosis [36]. Accordingly, low concentrations of genta-
micin, as used in the current study, may elicit different toxic
responses and by alternate cellular mechanisms than for higher
doses and thus may have greater relevance in understanding the
proximal tubular toxicity of the AGAs.
The use of AGAs with lower nephrotoxic potential, such as
amikacin, isepamacin or even the C2 gentamicin congener [37] in
addition to the use of single daily dosingwill lead to a reduction in
the prevalence of AGA nephrotoxicity where employed. How-
ever due to its low cost, gentamicin therapy continues to be
widely-used globally and thus it remains important to understand
the molecular cause(s) of the proximal tubule injury particularly if
an economical cotreatment adjunct such as lithium can be shown
to be an effective ameliorant. In this regard, it will be necessary
next to show that lithium actually ameliorates AGA-induced
nephrotoxicity in vivo, for example in rats.
The physiological function(s) of the proximal tubular CaR
may include the regulation of volume absorption, vitamin D
1α-hydroxylation and phosphate reabsorption [21,38–40]. We
propose therefore that during AGA therapy the presence of
luminal gentamicin may cause additional and excessive acti-
vation of the proximal tubular CaR causing sustained receptor-
induced signalling leading to apoptotic cell death and that this
should now be tested in an animal model. Together, these data
implicate the CaR and a lithium-inhibitable signalling pathway
in the mediation of gentamicin toxicity in proximal tubular-
derived OK cells and CaR-HEK cells.
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